LEADER 04211nam 2200577 a 450 001 9910438132903321 005 20200520144314.0 010 $a1-283-91160-4 010 $a1-4471-4132-6 024 7 $a10.1007/978-1-4471-4132-7 035 $a(CKB)2670000000246547 035 $a(EBL)1081710 035 $a(OCoLC)810446785 035 $a(SSID)ssj0000766954 035 $a(PQKBManifestationID)11943487 035 $a(PQKBTitleCode)TC0000766954 035 $a(PQKBWorkID)10739596 035 $a(PQKB)10102668 035 $a(DE-He213)978-1-4471-4132-7 035 $a(MiAaPQ)EBC1081710 035 $a(PPN)168292696 035 $a(EXLCZ)992670000000246547 100 $a20120730d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCardiac valvular medicine /$fNalini M. Rajamannan, editor 205 $a1st ed. 2013. 210 $aNew York $cSpringer$d2013 215 $a1 online resource (255 p.) 300 $aDescription based upon print version of record. 311 $a1-4471-4131-8 320 $aIncludes bibliographical references and index. 327 $a1.Natural History of Aortic Valve Stenosis -- 2. Cardiovascular Risk Factors for Calcific Aortic Valve Disease -- 3.Bicuspid Aortic Valve Disease: From Bench to Bedside -- 4.Experimental Evidence for the Role of Atherosclerosis in Calcific Aortic Valve Disease -- 5.The Electrocardiogram as a Risk Predictor in Asymptomatic Aortic Stenosis -- 6.Exercise Testing in Aortic Stenosis and in Mitral Regurgitation -- 7. Detection of Calcium in the Aortic Valve by Non- Invasive Imaging -- 8.Assessment of Aortic Stenosis Severity:Determining Timing to Surgery -- 9.Balloon Aortic Valvuloplasty -- 10.Imaging for TAVI -- 11.Transcutaneous Aortic Valve Implantation -- 12.Role of statins in valvular heart disease: Rheumatic valve disease and bioprosthetic valves -- 13.Slowing the Progression of Aortic Stenosis ? The Emerging Role of Bisphosphonates -- 14.LDL-Density-Theory:Implications for Future Clinical Trials -- 15.Infective Endocarditis: New Recommendations and Perspectives -- 16.Assessment and Timing to Intervention of Mitral Regurgitation -- 17. Biology of Mitral Valve Disease -- 18.Mitral Valve Devices -- 19.Anatomy and Pathology of Right-sided atrioventricular and semilunal valves -- 20.Mechanisms, Evaluation and Management of Tricuspid Regurgitation. 330 $aExperimental studies in the field of cardiac valve biology are now demonstrating that the cardiac valve disease process is an active biology with risk factors analogous to vascular risk factors.  Understanding the risk factors is also evolving rapidly, giving physicians and scientists insight into the cellular mechanisms and raising the possibility of treating these valve lesions with other options besides surgical valve repair. Our knowledge of right-sided valve lesions is also rapidly becoming important in the field of valvular medicine. Not only is the pathology different from left-sided valve lesions, but the hemodynamic compromise is more complex and difficult to treat in patients who develop tricuspid or pulmonic valve disease. Early diagnosis and careful management of this patient population is critical for long term outcomes in this patient population.   Cardiac Valvular Medicine represents an overview of the most recent science, clinical trials and new discoveries in the field of valvular heart disease. The editor has assembled a team of highly experienced contributors to provide a thorough translational understanding of the current and future treatments for this patient population. Cardiologists, internists, family practice physicians, cardiac surgeons and basic scientists will all find enormous benefit from this textbook. 606 $aHeart valves$xDiseases 606 $aCardiology 615 0$aHeart valves$xDiseases. 615 0$aCardiology. 676 $a616.1 676 $a616.122 701 $aRajamannan$b Nalini M$0787350 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910438132903321 996 $aCardiac valvular medicine$94187292 997 $aUNINA